THYTECH

ThyTech is a preclinical-stage biotechnology company focused on thymus regeneration and the restoration of T-cell immunity. Spun out from the German Cancer Research Center (DKFZ), the company utilizes a proprietary platform to develop bioengineered thymus tissue and organoids. Their primary goal is to treat severe immunodeficiencies, including DiGeorge syndrome and age-related immune decline, by providing a functional environment for T-cell maturation. ThyTech's technology also holds potential for improving outcomes in hematopoietic stem cell transplantation and cancer immunotherapy. The company is headquartered in Heidelberg, Germany, and is led by pioneers in thymus biology.